More than 40% of cancer drugs granted accelerated approval from 2013 to 2017 did not demonstrate clinical benefit in confirmatory trials, according to a study in the Journal of the American Medical Association (JAMA). The paper ‘Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval’ reviewed 46 drugs granted approval under the US […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
